Upstream Bio (UPB) Common Equity (2023 - 2025)
Historic Common Equity for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to $378.6 million.
- Upstream Bio's Common Equity rose 33615.6% to $378.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $378.6 million, marking a year-over-year increase of 33615.6%. This contributed to the annual value of $469.9 million for FY2024, which is 48160.26% up from last year.
- As of Q3 2025, Upstream Bio's Common Equity stood at $378.6 million, which was up 33615.6% from $408.7 million recorded in Q2 2025.
- In the past 5 years, Upstream Bio's Common Equity ranged from a high of $469.9 million in Q4 2024 and a low of -$160.3 million during Q3 2024
- Moreover, its 3-year median value for Common Equity was -$112.2 million (2023), whereas its average is $114.1 million.
- Over the last 5 years, Upstream Bio's Common Equity had its largest YoY gain of 48160.26% in 2024, and its largest YoY loss of 4287.46% in 2024.
- Quarter analysis of 3 years shows Upstream Bio's Common Equity stood at -$123.1 million in 2023, then soared by 481.6% to $469.9 million in 2024, then fell by 19.42% to $378.6 million in 2025.
- Its Common Equity stands at $378.6 million for Q3 2025, versus $408.7 million for Q2 2025 and $445.6 million for Q1 2025.